Copyright
©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 384-392
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.384
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.384
Table 1 Case reports of conversion hepatectomy after lenvatinib treatment
| Ref. | Age/sex | Background disease | Regimen | Reason for unresectivity | Former treatment | Child-Pugh classification | Duration | RDI (%) | Type of hepatectomy | Prognosis |
| Sato et al[23] (2019) | 66/F | HCV | Lenvatinib | Large size | TACE | 8 (B) | 6 mo | 70 | Extended right hepatectomy | 3 mo alive with no recurrence |
| Chen et al[26] (2019) | 69/F | HBV | Lenvatinib, nivolmab | Large size | Sorafenib TACE | 8 (B) | 3.5 mo | 100 | Extended right hepatectomy | 3 mo alive with no recurrence |
| Takahashi et al[25] (2019) | 82/F | Non B/C | Lenvatinib | Lung metastasis | None | 5 (A) | 13 mo | 38 | Extended posterior segmentectomy | 5 mo alive with no recurrence |
| Present study | 59/M | HCV | Lenvatinib | PVTT (Vp4) | None | 5 (A) | 3 mo | 100 | Left hepatectomy | 8 mo alive with no recurrence |
- Citation: Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392
- URL: https://www.wjgnet.com/1948-5182/full/v13/i3/384.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i3.384